Filing Details

Accession Number:
0000899243-22-022785
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-06-16 16:05:13
Reporting Period:
2022-06-14
Accepted Time:
2022-06-16 16:05:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1274792 Merrimack Pharmaceuticals Inc MACK Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1548707 Newtyn Partners, Lp 60 East 42Nd Street, 9Th Floor
New York NY 10165
No No No Yes
1548709 Newtyn Te Partners, Lp 60 East 42Nd Street, 9Th Floor
New York NY 10165
No No No Yes
1569241 Newtyn Management, Llc 60 East 42Nd Street, 9Th Floor
New York NY 10165
No No No Yes
1788608 G. Noah Levy 60 East 42Nd Street, 9Th Floor
New York NY 10165
Yes No No Yes
1789643 Newtyn Capital Partners, Lp 60 East 42Nd Street, 9Th Floor
New York NY 10165
No No No Yes
1789647 Ledo Capital, Llc 60 East 42Nd Street, 9Th Floor
New York NY 10165
No No No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-06-14 11,977 $5.17 1,010,515 No 4 P Indirect See footnote
Common Stock Acquisiton 2022-06-14 8,961 $5.17 740,120 No 4 P Indirect See footnote
Common Stock Acquisiton 2022-06-15 1,659 $5.37 1,012,174 No 4 P Indirect See footnote
Common Stock Acquisiton 2022-06-15 1,241 $5.37 741,361 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
  2. The shares are directly held by NP. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
  4. The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.